Ionis Pharmaceuticals (IONS) Selling Pressure 'Unwarranted' - BMO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq set to open higher as CPI, bank earnings take focus; IBM tumbles
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Biogen (BIIB) Weakness Overdone on Spinraza Death Fears - Mizuho
September 29, 2017 11:31 AM EDTMizuho Securities analyst Salim Syed defended Biogen (NASDAQ: BIIB) amid worries about Spinraza deaths after the FDA made its FAERS (FDA Adverse Events Reporting System) searchable by drug yesterday.
Today there is a link in circulation showing there have been 9 deaths with Spinraza.... More
Ionis Pharma (IONS) Says Deaths Not Surprising as SMA Patients Die Early - Bloomberg
September 29, 2017 10:14 AM EDTIonis Pharma (NASDAQ: IONS) Says Deaths Not Surprising as SMA Patients Die Early - Bloomberg
... MoreSarepta Therapeutics (SRPT), Ionis Pharma (IONS) Weakness Related Taking Reports Out of Context - Adam F
September 29, 2017 10:07 AM EDTAdam Feurstein weighs in on Ionis Pharma (NASDAQ: IONS) and Sarepta Therapeutics (NASDAQ: SRPT), saying weakness could be from taking death reports out of context.
Todays pastime seems to be searching FDAs FAERS database and tweeting side effects/deaths out of context. $IONS $SRPT
Adam Feuerstein (@adamfeuerstein) September 29, 2017... MoreIonis Pharma (IONS) Pressured, Down 3.5%
September 29, 2017 9:50 AM EDTIonis Pharma (NASDAQ: IONS) Pressured, Down 3.5%
... More